Careers
News and Events
Investors
Find solutions
Business Challenges
Strategic partnering
Biosimilar development and marketing
Early sell or out-license?
Acquire or partner, develop, market
Discover, develop, market
Acquire to distribute
Manage product lifecycle
Acquire, develop, and sell
Risk management
Pharmacovigilance
Emerging Regions
Clinical Stages
Early stage studies: Phase I/IIa
Pivotal clinical trials: Phase IIb/III
Peri-approval/post-marketing studies: Phase IIIb/IV
Therapy
Cardiovascular and metabolic diseases
Central nervous system (CNS) disorders
Infectious disease
Oncology and hematology
Other therapeutic areas
The PAREXEL difference
About
Management team
Find an office
Experience and expertise
eClinical innovation
Businesses we serve
Why PAREXEL?
Services and Capabilities
PAREXEL Consulting
Early Phase
Clinical Research
Peri/Post Approval
Medical Communications
PAREXEL Akademie
Technology
ClinPhone RTSM
Imaging
CTMS
EDC
ePRO
Solutions
Find an expert in:
Country...
United States
Afghanistan
Albania
Algeria
Andorra
Angola
Antigua and Barbuda
Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo
Costa Rica
C+¦te d'Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Fiji
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Korea, North
Korea, South
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia, Federated States of
Moldova
Monaco
Mongolia
Montenegro
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Rwanda
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and The Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Western Sahara
Yemen
Zambia
Zimbabwe
Find an expert on:
Topic / Service...
Phase I/IIa
Phase II/IIIa
Phase IIIb/IV
Therapeutic Expertise
Reimbursement / Market Access
Development / Commercialization
Regulatory Compliance
Patient Recruiting
Clinical Logistics
Clinical Technology
Safety & Risk Management
Medical Communications
About
Management team
Find an office
Experience and expertise
eClinical innovation
Businesses we serve
Why PAREXEL?
Advanced contact
News and events
Services and capabilities
PAREXEL Consulting
Early Phase
Clinical Research
Late Phase
Medical Communications
PAREXEL Akademie
Clinical stages
Early stage studies: Phase I/IIa
Pivotal clinical trials: Phase IIb/III
Peri-approval/post-marketing studies: Phase IIIb/IV
Therapies
Cardiovascular and metabolic diseases
Central nervous system (CNS) disorders
Infectious disease
Oncology and hematology
Other therapeutic areas
Technology
ClinPhone RTSM
Imaging
CTMS
EDC
ePRO
Solutions
Business Challenges
Strategic partnering
Biosimilar development and marketing
Early sell or out-license?
Acquire or partner, develop, market
Discover, develop, market
Acquire to distribute
Manage product lifecycle
Acquire, develop, and sell
Risk management
Pharmacovigilance
Emerging Regions
